{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:02Z","timestamp":1793262002933,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-10003-y","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T09:02:12Z","timestamp":1729501332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lomitapide: navigating cardiovascular challenges with innovative therapies"],"prefix":"10.1007","volume":"51","author":[{"given":"Undral","family":"Munkhsaikhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Ait-Aissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"Sahyoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsanul Hoque","family":"Apu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammaar H.","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modar","family":"Kassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"1","key":"10003_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35772\/ghm.2020.01078","volume":"3","author":"H Yanai","year":"2021","unstructured":"Yanai H, Yoshida H (2021) Secondary dyslipidemia: its treatments and association with atherosclerosis. Glob Health Med 3(1):15\u201323","journal-title":"Glob Health Med"},{"issue":"7","key":"10003_CR2","doi-asserted-by":"crossref","first-page":"e0269531","DOI":"10.1371\/journal.pone.0269531","volume":"17","author":"M Chhabra","year":"2022","unstructured":"Chhabra M et al (2022) Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies. PLoS ONE 17(7):e0269531","journal-title":"PLoS ONE"},{"key":"10003_CR3","doi-asserted-by":"crossref","unstructured":"Munkhsaikhan U et al (2023) The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr(-\/-) mice with obesity. Antioxid (Basel), 12(6)","DOI":"10.3390\/antiox12061287"},{"issue":"4","key":"10003_CR4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/oby.23389","volume":"30","author":"U Munkhsaikhan","year":"2022","unstructured":"Munkhsaikhan U et al (2022) The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity. Obes (Silver Spring) 30(4):893\u2013901","journal-title":"Obes (Silver Spring)"},{"issue":"9860","key":"10003_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381(9860):40\u201346","journal-title":"Lancet"},{"issue":"1","key":"10003_CR6","doi-asserted-by":"crossref","first-page":"21058","DOI":"10.1038\/s41598-023-47872-5","volume":"13","author":"A Gholamzad","year":"2023","unstructured":"Gholamzad A et al (2023) Association between serum vitamin D levels and lipid profiles: a cross-sectional analysis. Sci Rep 13(1):21058","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10003_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1007787713191","volume":"11","author":"U de Faire","year":"1997","unstructured":"de Faire U et al (1997) Retardation of coronary atherosclerosis: the Bezafibrate Coronary atherosclerosis intervention trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther 11(Suppl 1):257\u2013263","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10003_CR8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbrc.2015.09.003","volume":"466","author":"Z Li","year":"2015","unstructured":"Li Z, Cheng J, Wang L (2015) Edaravone attenuates monocyte adhesion to endothelial cells induced by oxidized low-density lipoprotein. Biochem Biophys Res Commun 466(4):723\u2013727","journal-title":"Biochem Biophys Res Commun"},{"key":"10003_CR9","doi-asserted-by":"crossref","unstructured":"Morofuji Y et al (2022) Beyond Lipid-Lowering: effects of statins on Cardiovascular and Cerebrovascular diseases and Cancer. Pharmaceuticals (Basel), 15(2)","DOI":"10.3390\/ph15020151"},{"key":"10003_CR10","doi-asserted-by":"crossref","unstructured":"Wang A et al (2016) Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc, 5(7)","DOI":"10.1161\/JAHA.116.003294"},{"key":"10003_CR11","doi-asserted-by":"crossref","unstructured":"Yang CH et al (2021) Regulation of pancreatic \u03b2-Cell function by the NPY System. Endocrinology, 162(8)","DOI":"10.1210\/endocr\/bqab070"},{"issue":"2","key":"10003_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.RV17029","volume":"26","author":"Y Ishigaki","year":"2019","unstructured":"Ishigaki Y et al (2019) Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb 26(2):121\u2013127","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10003_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pcad.2018.07.003","volume":"61","author":"A Elagizi","year":"2018","unstructured":"Elagizi A et al (2018) An overview and update on obesity and the obesity Paradox in Cardiovascular diseases. Prog Cardiovasc Dis 61(2):142\u2013150","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"10003_CR14","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1053\/j.gastro.2007.03.055","volume":"132","author":"S Parekh","year":"2007","unstructured":"Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132(6):2191\u20132207","journal-title":"Gastroenterology"},{"issue":"2","key":"10003_CR15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","volume":"71","author":"EA Enas","year":"2019","unstructured":"Enas EA et al (2019) Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J 71(2):99\u2013112","journal-title":"Indian Heart J"},{"issue":"8","key":"10003_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ et al (2020) Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 383(8):711\u2013720","journal-title":"N Engl J Med"},{"issue":"2","key":"10003_CR17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD (2012) Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223(2):262\u2013268","journal-title":"Atherosclerosis"},{"key":"10003_CR18","doi-asserted-by":"crossref","unstructured":"Behbodikhah J et al (2021) Apolipoprotein B and Cardiovascular Disease: Biomarker and potential therapeutic target. Metabolites, 11(10)","DOI":"10.3390\/metabo11100690"},{"issue":"3","key":"10003_CR19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOL.0b013e32836139df","volume":"24","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Rader DJ (2013) Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 24(3):246\u2013250","journal-title":"Curr Opin Lipidol"},{"key":"10003_CR20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.athplu.2021.05.001","volume":"43","author":"MG Lupo","year":"2021","unstructured":"Lupo MG et al (2021) Lomitapide does not alter PCSK9 and lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile. Atherosclerosis Plus 43:7\u20139","journal-title":"Atherosclerosis Plus"},{"key":"10003_CR21","unstructured":"Feingold KR et al (2000) Cholesterol Lowering Drugs, in Endotext, K.R. Feingold, Editors. MDText.com, Inc. Copyright \u00a9 2000\u20132024, MDText.com, Inc.: South Dartmouth (MA)"},{"issue":"1","key":"10003_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12944-019-1075-7","volume":"18","author":"X Guan","year":"2019","unstructured":"Guan X et al (2019) Emerging roles of low-density lipoprotein in the development and treatment of breast cancer. Lipids Health Dis 18(1):137","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10003_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1388-1981(00)00123-2","volume":"1488","author":"T Hevonoja","year":"2000","unstructured":"Hevonoja T et al (2000) Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 1488(3):189\u2013210","journal-title":"Biochim Biophys Acta"},{"key":"10003_CR24","doi-asserted-by":"crossref","first-page":"826379","DOI":"10.3389\/fcell.2022.826379","volume":"10","author":"MM Islam","year":"2022","unstructured":"Islam MM, Hlushchenko I, Pfisterer SG (2022) Low-density lipoprotein internalization, degradation and receptor recycling along membrane contact sites. Front Cell Dev Biol 10:826379","journal-title":"Front Cell Dev Biol"},{"key":"10003_CR25","doi-asserted-by":"crossref","unstructured":"Srivastava RAK (2023) A review of progress on targeting LDL receptor-dependent and -Independent pathways for the Treatment of Hypercholesterolemia, a major risk factor of ASCVD. Cells, 12(12)","DOI":"10.3390\/cells12121648"},{"issue":"11","key":"10003_CR26","first-page":"e48865","volume":"15","author":"P Das","year":"2023","unstructured":"Das P, Ingole N (2023) Lipoproteins and their effects on the Cardiovascular System. Cureus 15(11):e48865","journal-title":"Cureus"},{"key":"10003_CR27","doi-asserted-by":"crossref","first-page":"152786","DOI":"10.1155\/2013\/152786","volume":"2013","author":"A Pirillo","year":"2013","unstructured":"Pirillo A, Norata GD, Catapano AL (2013) LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013:152786","journal-title":"Mediators Inflamm"},{"key":"10003_CR28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yjmcc.2016.07.003","volume":"98","author":"A Sirker","year":"2016","unstructured":"Sirker A et al (2016) Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. J Mol Cell Cardiol 98:11\u201317","journal-title":"J Mol Cell Cardiol"},{"key":"10003_CR29","doi-asserted-by":"crossref","first-page":"670076","DOI":"10.3389\/fphar.2021.670076","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Jose PA (2021) Coordinated contribution of NADPH oxidase- and mitochondria-derived reactive oxygen species in metabolic syndrome and its implication in renal dysfunction. Front Pharmacol 12:670076","journal-title":"Front Pharmacol"},{"key":"10003_CR30","doi-asserted-by":"crossref","unstructured":"Vermot A et al (2021) NADPH oxidases (NOX): an overview from Discovery, Molecular mechanisms to Physiology and Pathology. Antioxid (Basel), 10(6)","DOI":"10.3390\/antiox10060890"},{"key":"10003_CR31","doi-asserted-by":"crossref","unstructured":"Hartley L et al (2016) Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2016(1): p. Cd011472.","DOI":"10.1002\/14651858.CD011472.pub2"},{"issue":"4","key":"10003_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0003319712465171","volume":"64","author":"AT Al-Hinai","year":"2013","unstructured":"Al-Hinai AT et al (2013) First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Angiology 64(4):287\u2013292","journal-title":"Angiology"},{"issue":"5","key":"10003_CR33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7150\/ijbs.14027","volume":"12","author":"Y Zhang","year":"2016","unstructured":"Zhang Y et al (2016) Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated Organ Injury. Int J Biol Sci 12(5):569\u2013579","journal-title":"Int J Biol Sci"},{"issue":"21","key":"10003_CR34","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/CIRCULATIONAHA.121.056536","volume":"144","author":"NA Marston","year":"2021","unstructured":"Marston NA et al (2021) Cardiovascular Benefit of lowering low-density lipoprotein cholesterol below 40\u00a0mg\/dL. Circulation 144(21):1732\u20131734","journal-title":"Circulation"},{"key":"10003_CR35","doi-asserted-by":"crossref","unstructured":"Alonso R et al (2024) Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: the SAFEHEART follow-up study. Atherosclerosis, : p. 117516","DOI":"10.1016\/j.atherosclerosis.2024.117516"},{"issue":"8","key":"10003_CR36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","volume":"22","author":"C Stefanutti","year":"2020","unstructured":"Stefanutti C (2020) Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep 22(8):38","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10003_CR37","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ (2014) Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9):1022\u20131032","journal-title":"Circulation"},{"issue":"4","key":"10003_CR38","first-page":"669","volume":"14","author":"RN Pejic","year":"2014","unstructured":"Pejic RN (2014) Familial hypercholesterolemia. J 14(4):669\u2013672Ochsner","journal-title":"J"},{"issue":"2","key":"10003_CR39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2006.02.023","volume":"190","author":"JC Hogue","year":"2007","unstructured":"Hogue JC et al (2007) Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 190(2):429\u2013435","journal-title":"Atherosclerosis"},{"issue":"1","key":"10003_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","volume":"16","author":"L D\u2019Erasmo","year":"2021","unstructured":"D\u2019Erasmo L et al (2021) Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet J Rare Dis 16(1):381","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"10003_CR41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11789-012-0049-3","volume":"7","author":"P Schuff-Werner","year":"2012","unstructured":"Schuff-Werner P, Fenger S, Kohlschein P (2012) Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 7(Suppl 1):7\u201314","journal-title":"Clin Res Cardiol Suppl"},{"issue":"4","key":"10003_CR42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","volume":"23","author":"M Kayikcioglu","year":"2021","unstructured":"Kayikcioglu M (2021) LDL apheresis and lp (a) apheresis: a clinician\u2019s perspective. Curr Atheroscler Rep 23(4):15","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10003_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5582\/irdr.2014.01031","volume":"4","author":"N Akamatsu","year":"2015","unstructured":"Akamatsu N, Sugawara Y, Kokudo N (2015) Budd-Chiari syndrome and liver transplantation. Intractable Rare Dis Res 4(1):24\u201332","journal-title":"Intractable Rare Dis Res"},{"issue":"2","key":"10003_CR44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M et al (2007) Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356(2):148\u2013156","journal-title":"N Engl J Med"},{"issue":"5","key":"10003_CR45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D\u2019Erasmo","year":"2017","unstructured":"D\u2019Erasmo L et al (2017) Efficacy of Lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther 34(5):1200\u20131210","journal-title":"Adv Ther"},{"issue":"5","key":"10003_CR46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","volume":"29","author":"L D\u2019Erasmo","year":"2022","unstructured":"D\u2019Erasmo L et al (2022) Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-european retrospective observational study. Eur J Prev Cardiol 29(5):832\u2013841","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10003_CR47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","volume":"14","author":"JA Underberg","year":"2020","unstructured":"Underberg JA et al (2020) Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide evaluation Registry (LOWER). J Clin Lipidol 14(6):807\u2013817","journal-title":"J Clin Lipidol"},{"key":"10003_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","volume":"359","author":"AB Cefal\u00f9","year":"2022","unstructured":"Cefal\u00f9 AB et al (2022) Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis 359:13\u201319","journal-title":"Atherosclerosis"},{"issue":"3","key":"10003_CR49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","volume":"174","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Stanesa M, Hegele RA (2014) Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with lomitapide. JAMA Intern Med 174(3):443\u2013447","journal-title":"JAMA Intern Med"},{"key":"10003_CR50","doi-asserted-by":"crossref","first-page":"937750","DOI":"10.3389\/fgene.2022.937750","volume":"13","author":"L D\u2019Erasmo","year":"2022","unstructured":"D\u2019Erasmo L et al (2022) Efficacy of long-term treatment of autosomal recessive hypercholesterolemia with Lomitapide: a subanalysis of the Pan-european Lomitapide Study. Front Genet 13:937750","journal-title":"Front Genet"},{"issue":"9","key":"10003_CR51","doi-asserted-by":"crossref","first-page":"e0138609","DOI":"10.1371\/journal.pone.0138609","volume":"10","author":"AM Gamez-Mendez","year":"2015","unstructured":"Gamez-Mendez AM et al (2015) Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS ONE 10(9):e0138609","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"10003_CR52","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1038\/sj.cdd.4401451","volume":"11","author":"RC Austin","year":"2004","unstructured":"Austin RC, Lentz SR, Werstuck GH (2004) Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11(Suppl 1):S56\u201364","journal-title":"Cell Death Differ"},{"key":"10003_CR53","doi-asserted-by":"crossref","unstructured":"Silva IVG, de Figueiredo RC, Rios DRA (2019) Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci, 20(14)","DOI":"10.3390\/ijms20143458"},{"issue":"10","key":"10003_CR54","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI0216784","volume":"110","author":"D Ron","year":"2002","unstructured":"Ron D (2002) Translational control in the endoplasmic reticulum stress response. J Clin Invest 110(10):1383\u20131388","journal-title":"J Clin Invest"},{"issue":"19","key":"10003_CR55","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1042\/CS20190648","volume":"133","author":"M Miyao","year":"2019","unstructured":"Miyao M et al (2019) Endoplasmic reticulum stress and mitochondrial biogenesis are potential therapeutic targets for abdominal aortic aneurysm. Clin Sci (Lond) 133(19):2023\u20132028","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10003_CR56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12929-017-0357-5","volume":"24","author":"A Ghosh","year":"2017","unstructured":"Ghosh A et al (2017) Role of free fatty acids in endothelial dysfunction. J Biomed Sci 24(1):50","journal-title":"J Biomed Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-10003-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:42:52Z","timestamp":1738730572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-10003-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10003"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-10003-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1082"}}